NCT03753919 2026-03-11
DUTHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Terminated
Clinical Trials
100 trialsNCT04785287 2026-03-03
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated
NCT03211988 2026-03-02
Entinostat Neuroendocrine (NE) Tumor
Columbia University
Phase 2 Terminated
NCT03165721 2026-02-18
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04187404 2026-01-30
Spencer
Enterome
Phase 1/2 Terminated
NCT05014698 2026-01-28
IDENTHY-K
Nantes University Hospital
Phase NA Terminated
NCT05987176 2026-01-14
NELMAS
Imperial College London
Phase 2 Terminated
NCT03746431 2026-01-07
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Fusion Pharmaceuticals Inc.
Phase 1 Terminated
NCT04042714 2025-11-04
TAS-102 NEC
Baylor Research Institute
Phase 2 Terminated
NCT04985604 2025-10-02
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 2 Terminated
NCT05420636 2025-07-30
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
Fox Chase Cancer Center
Phase 2 Terminated
NCT04579679 2025-07-25
Open-Label Surufatinib in European Patients With NET
Hutchmed
Phase 2 Terminated
NCT03469011 2025-06-27
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
AHS Cancer Control Alberta
Phase 1 Terminated
NCT05634577 2025-06-19
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02010957 2025-06-10
FAMIAN
Wuerzburg University Hospital
Phase 3 Terminated
NCT03466216 2025-06-10
Phase 1 Study of AlphaMedixâ„¢ in Adult Subjects With SSTR (+) NET
Orano Med LLC
Phase 1 Terminated
NCT07012330 2025-06-10
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Erasmus Medical Center
Phase 2 Terminated
NCT04579757 2025-05-08
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT05003856 2025-04-02
Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule
M.D. Anderson Cancer Center
Phase NA Terminated
NCT03387592 2025-03-10
SENECA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT02464007 2025-02-25
Study of rSIFN-co for Patients With Advanced Solid Tumors
Sichuan Huiyang Life Science and Technology Corporation
Phase 1 Terminated
NCT04538378 2025-01-27
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02489604 2025-01-13
LUNET
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT02736448 2025-01-13
Lu-Ca-S
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT05500508 2024-12-24
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
Phase 1/2 Terminated
NCT05999292 2024-12-09
Phase 1 Study of 68Ga-R8760
Radionetics Oncology
Phase 1 Terminated
NCT04605848 2024-05-09
MICROBAT
University of Avignon
Phase NA Terminated
NCT01246739 2024-04-10
AUSC
Region Skane
Phase NA Terminated
NCT03420521 2024-01-09
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT04452396 2023-12-12
CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia
Barts & The London NHS Trust
Phase NA Terminated
NCT02859064 2023-12-05
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT03724409 2023-11-28
Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases
University of Iowa
Phase EARLY_PHASE1 Terminated
NCT02592707 2023-07-19
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
Ipsen
Phase 1/2 Terminated
NCT03986593 2023-07-05
Cryoablation of Bone Metastases From Endocrine Tumors
Instituto do Cancer do Estado de São Paulo
Phase NA Terminated
NCT02031536 2023-06-29
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00227617 2023-05-22
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Phase 2/3 Terminated
NCT03515603 2023-05-17
Endocrine Outcome of Surgery for Pituitary Adenoma
University of Ulm
Phase NA Terminated
NCT05338125 2023-03-13
Electrophysiology of the Human Pituitary Gland
Leiden University Medical Center
Phase NA Terminated
NCT04077372 2023-01-27
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
Stanford University
Phase NA Terminated
NCT02683941 2022-07-06
SPINET
Ipsen
Phase 3 Terminated
NCT02419664 2022-03-31
Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
Göteborg University
Phase 3 Terminated
NCT03602495 2021-12-13
DTC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Terminated
NCT01861717 2021-09-30
A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
Saint John's Cancer Institute
Phase 4 Terminated
NCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03190213 2021-06-22
Pembro NEC
University of Utah
Phase 2 Terminated
NCT03670030 2021-06-10
A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
Ochsner Health System
Phase 2 Terminated
NCT04073017 2021-05-21
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency
Vanderbilt-Ingram Cancer Center
Phase NA Terminated
NCT02749227 2021-04-27
PASSILCORT
Columbia University
Phase 2 Terminated
NCT02743442 2021-03-29
ROBOPHYSE
Fondation Ophtalmologique Adolphe de Rothschild
Phase NA Terminated